Journal
Spotlights
Webinars
Channels
Analytics
Manufacturing
Vectors
Regulatory
Supply Chain
Translational Research & Clinical Development
Business and Finance
Reports
Regulatory Insights
Clinical Trends
Innovation Insights
Business Insights
Investor Insights
FastFacts
Media Kit
Media Kit
Editorial calendar
Sponsorship opportunities
Webinars
About
Submit your manuscript
Meet the team
Get in touch
Immuno-Oncology Insights
Login
Register
Update your profile
Logout
CELL & GENE THERAPY
INSIGHTS
Search
Latest Spotlight
Previous Spotlights
Vector bioprocessing – April 2022
Guest Editor:
Franz Gerner, Chief Technology Officer at Excision BioTherapeutics
Franz Gerner
Chief Technology Officer at Excision BioTherapeutics
Manufacturing of RCA-free adenoviral vectors
N Scheer
Nico Scheer
Senior Consultant Business Development, CEVEC Pharmaceuticals
27 March 2022
Poster
Thinking big: the need for innovation in the production of lentivirus-based...
H Leinonen,
J Moscariello,
L Davies
et al.
Hanna Leinonen
Senior Scientist, Kuopio Center for Gene and Cell Therapy
John Moscariello
Executive Director, Viral Vector and Gene Editing Process Development, Bristol Myers Squibb
Lee Davies
Director, Process Research & Development, Oxford Biomedica
Scott Cross
Senior Principal, Dark Horse Consulting
Will Junker
Head of Vector Manufacturing Quality, Kite Pharma
23 April 2022
Expert Roundtable Video
Flexible & scalable solutions for AAV viral vector production using...
E Fong
Eva Fong
Principle Scientist, Virus and Gene Therapy Bioprocessing
20 April 2022
Innovator Insight
Clarification of recombinant adeno-associated virus (rAAV) & lentivirus...
R Chinnawar
N Marchand
Rajeshwar Chinnawar
at Pall
Nicholas Marchand
R&D Engineer at Pall Biotech
3 May 2022
Research Article
Vector bioprocessing spotlight
F Gerner
Future trends in viral vector process & product development
R Krishna
Considerations for demonstrating comparability of AAV processes
L Giersch
Accelerating cell & gene therapy workflows with next-generation analytical tools
C Heger, PhD
View all
Sponsors
Raw and starting materials
1 March 2022
Preclinical and translational tools and strategies
16 February 2022
Tools of tomorrow
1 December 2021
Cell therapy bioprocessing and automation
1 November 2021
Gene therapy CMC and quality control
1 October 2021
New horizons for cell therapy: emerging platforms
1 October 2021
View all
Upcoming webinars
On Demand Webinars
Streamlined workflow solutions for cell and gene therapy analytics
A Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
7
Days
7
Hrs
24
Min
Register
Improving T cell therapy manufacturing processes with automation and...
E Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
9
Days
7
Hrs
24
Min
Register
Life on a chip - vascularized micro-tumor chips for mimicking clinical...
C Hughes
Chris Hughes
CSO at Aracari Biosciences
8 Jun 2022
22
Days
7
Hrs
24
Min
Register
Thinking translational: Things to consider in CAR T cell research workflows
S Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
7
Hrs
24
Min
Register
Optimizing E. Coli cell growth performance with in-line, real-time OD600...
T Buch
R Shanbaky
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
15
Hrs
24
Min
Register
Accelerating cell therapy discovery & development with non-viral gene...
D Hermanson
X Patrinostro
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
29
Days
15
Hrs
24
Min
Register
Monitoring of circulating CAR T cells
A Graband,
D Hünecke,
D Bremm
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
7
Hrs
24
Min
Register
Applying an HPLC analytical platform for mRNA process monitoring
N Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
7
Hrs
24
Min
Register
View all
Strategic partnering to enable cell therapy commercialization
J Smith
X de Mollerat du Jeu
Jenessa Smith
Associate Director of Process Development at ArsenalBio
Xavier de Mollerat du Jeu
Senior Director, R&D, Cell and Gene Therapy at Thermo Fisher Scientific
12 May 2022
Watch now
From cells to purified capsids: How to develop a scalable rAAV process
Å Hagner McWhirter
Åsa Hagner McWhirter
Principal Scientist at Cytiva
3 May 2022
Watch now
Strategic supply chain design: flexibility and scalability considerations for...
N Kulkarni, PhD
G Linton, RA, AIA, LEED AP BD+C
Niranjan Kulkarni, PhD
Senior Director, Consulting Services at CRB
Grace Linton, RA, AIA, LEED AP BD+C
Director of Process Architecture at CRB
28 April 2022
Watch now
Manufacturing considerations for viral and non-viral platform selection
V Slepushkin,
A Noyes,
A Hagerman
et al.
Vladimir Slepushkin
Global Head of Manufacturing at MedTherapy Biotech
Aaron Noyes
Vice President of Development at Codiak Biosciences
Allison Hagerman
Vice President, Product Development, Oncolytics Biotech
Laurens Sierkstra
Senior Director, Business Leader, Purification at Thermo Fisher Scientific
10 May 2022
Watch now
Process development excellence to de-risk and accelerate commercialization...
B Baghbaderani
Behnam Baghbaderani
Global Head, Process Development, Emerging Technologies at Lonza Pharma & Biotech
5 May 2022
Watch now
Removing technological barriers to efficient large-scale LV vector production
R Lopez de Maturana,
E Jackson-Holmes,
M Neri
et al.
Rakel Lopez de Maturana
Qualified Person at VIVEbioTech
Emily Jackson-Holmes
Associate Product Manager at Thermo Fisher Scientific
Margherita Neri
Vector Process Development Manager at AGC Biologics
Steven G. Milian
Senior Staff Scientist (Process Sciences), Science & Technology Pharma Services Viral Vector Services at Thermo Fisher Scientific
Scott Jeffers
Gene Therapy Research and Process Development Leader at Redpin Therapeutics
26 April 2022
Watch now
View all
Channel content
Analytics
Manufacturing
Vectors
Regulatory
Supply Chain
Translational Research & Clinical Development
Business and Finance
Considerations for demonstrating comparability of AAV processes
L Giersch
Laura Giersch
Director of Technical Operations, Lysogene
25 April 2022
Viewpoint
Accelerating cell & gene therapy workflows with next-generation analytical...
C Heger, PhD
Chris Heger, PhD
Director, Applications Science, Analytical Solutions Division at Bio-techne
24 April 2022
Innovator Insight
Key considerations when adopting Droplet Digital PCR for viral vector...
M White
Mark White
Associate Director of Biopharma Product Marketing, Bio-Rad Laboratories
24 February 2022
FastFacts
View all
Fast chromatography of AAV – purification and analytics
M Leskovec
Maja Leskovec
Head of Process Development Viruses, BIA Separations, a Sartorius company
20 December 2021
FastFacts
Flexible & scalable solutions for AAV viral vector production using...
E Fong
Eva Fong
Principle Scientist, Virus and Gene Therapy Bioprocessing
20 April 2022
Innovator Insight
Rapid translation of a cellular therapeutic from research to clinic
A Patel
J Candiello
Ashish Patel
Civil Engineer
Joseph Candiello
Senior Product Manager at RoosterBio Inc
2 May 2022
Webinar Digest
View all
Fast chromatography of AAV – purification and analytics
M Leskovec
Maja Leskovec
Head of Process Development Viruses, BIA Separations, a Sartorius company
20 December 2021
FastFacts
Rapid Quantitation of Viral Vectors with Simple Plex Microfluidic Immunoassays
N Steere
Nathan Steere
Commercial Product Manager, Bio-Techne
20 December 2021
FastFacts
Flexible & scalable solutions for AAV viral vector production using...
E Fong
Eva Fong
Principle Scientist, Virus and Gene Therapy Bioprocessing
20 April 2022
Innovator Insight
View all
Current global regulatory landscape for biodistribution & shedding assessment...
N Schmidt,
J Giblin,
T MacLachlan
et al.
Natalie Anne Schmidt
Pfizer R & D Ltd., Global Regulatory Affairs, UK
Jon Giblin
Asphalion SL, Barcelona, Spain
Timothy K MacLachlan
Novartis Institutes for Biomedical Research, Cambridge, USA
Shera Dandapat
Janssen Research and Development, EMEA Regulatory Affairs, High Wycombe, UK
Gabor Veres
Pharmacoidea Ltd., Szeged, Hungary
Tatiana Anna Reimer
Bayer AG, Cell & Gene Therapy Unit, Germany
Martin Schulz
Pfizer Pharma GmbH, Berlin, Germany
Eva Hatzmann
Sanofi, Global Regulatory Affairs, NL
Andeleeb Dahy
Astellas Pharma Europe B.V., Leiden, NL
Gregory LaRosa
Pfizer Rare Disease Research Unit, Cambridge, MA, 01239, USA
Mimoun Azzouz
University of Sheffield, UK
Christopher J Mann
Asphalion SL, Barcelona, Spain
24 April 2022
Unproven stem cell-based interventions & harm to existing & future patients
F Naylor
K Matthews
Flora Naylor
Research Assistant Baker Institute for Public Policy, Rice University, Houston, TX USA
Kirstin RW Matthews
Fellow for Science and Technology Policy, Baker Institute for Public Policy, Rice University, Houston, TX USA
27 March 2022
Editorial
Standardization & analytical tool innovation in the cell & gene therapy...
F Atouf
Fouad Atouf
Vice President of Global Biologics, United States Pharmacopeia
3 March 2022
Interview
View all
Key factors in cell cryopreservation and impact on manufacturability...
R Newman
Robert Newman, PhD
Chief Scientific Officer, FUJIFILM Irvine Scientific
17 April 2022
FastFacts
Supply chain efficiency and sourcing for scaling your gene therapy operation
C Martin
D Young
Céline Martin
Senior Product Manager, Gene Therapy at Thermo Fisher Scientific
Don Young
Senior Global Product Manager, Single-Use Technologies at Thermo Fisher Scientific
5 May 2022
Poster
A collaborative approach to cell & gene therapy supply chain management
A Johnson
Anthony Johnson
Head of Supply Chain & Warehouse Cell and Gene Therapy Catapult
24 April 2022
Interview
View all
Unleashing the full potential of cell therapy through RNA engineering
M Kurtoglu
Metin Kurtoglu
Chief GMP Manufacturing and Chief Medical Officer at Cartesian Therapeutics
10 May 2022
Expert Insight
Overcoming the immune-related shortfalls of AAV
G Winslow
Genine Winslow
Founder & Chief Executive Officer at Chameleon Biosciences Inc
9 May 2022
Viewpoint
Breaking new ground in the clinical application of CRISPR/Cas9
L Sepp-Lorenzino
Laura Sepp-Lorenzino
Vice President, Head, Nucleic Acid Therapies at Vertex Pharmaceuticals Inc
9 May 2022
Interview
View all
Trends and considerations in cell and gene therapy M&A, partnering and...
E Townsend
Ewan Townsend
Partner, Arnold & Porter
10 May 2022
Interview
Early-stage investment in immuno oncology: riding the waves of hope...
J Lesterhuis,
H Mikkelsen,
J Tobin
et al.
W Joost Lesterhuis
Brandon Capital Partners, Melbourne VIC, Australia Telethon Kids Institute, Nedlands WA, Australia School of Biomedical Sciences, University of Western Australia, Crawley WA, Australia
Helga Mikkelsen
Brandon Capital Partners, Melbourne VIC, Australia
Jonathan Tobin
Brandon Capital Partners, Melbourne VIC, Australia
Michael Bettess
Brandon Capital Partners, Melbourne VIC, Australia
15 March 2022
Viewpoint
Immuno-oncology therapies: a looming mid-life crisis?
H Kim,
D Liew,
S Goodall
Hansoo Kim
Centre for Applied Health Economics, Griffith University, Australia
Danny Liew
Adelaide Medical School, The University of Adelaide, Australia
Stephen Goodall
Centre for Health Economic Research and Evaluation, University of Technology Sydney, Australia
15 March 2022
Commentary
View all
Reports
Regulatory Insights
Clinical Trends
Innovation Insights
Business Insights
Investor Insights
Regulatory Insights April 2022
13 April 2022
FEATURING
Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
N Schmidt,
J Giblin,
T MacLachlan
et al.
Unproven stem cell-based interventions & harm to existing & future patients
F Naylor,
K Matthews
“This is not a sustainable model.”
J DePinto,
R Richards
View all
Clinical Trends March 2022
16 March 2022
FEATURING
Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
N Schmidt,
J Giblin,
T MacLachlan
et al.
Unproven stem cell-based interventions & harm to existing & future patients
F Naylor,
K Matthews
“This is not a sustainable model.”
J DePinto,
R Richards
View all
Innovation Insights March 2022
16 March 2022
FEATURING
Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
N Schmidt,
J Giblin,
T MacLachlan
et al.
Unproven stem cell-based interventions & harm to existing & future patients
F Naylor,
K Matthews
“This is not a sustainable model.”
J DePinto,
R Richards
View all
Business Insights February 2022
16 February 2022
FEATURING
Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
N Schmidt,
J Giblin,
T MacLachlan
et al.
Unproven stem cell-based interventions & harm to existing & future patients
F Naylor,
K Matthews
“This is not a sustainable model.”
J DePinto,
R Richards
View all
Investor Insights October 2020
1 October 2020
FEATURING
Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
N Schmidt,
J Giblin,
T MacLachlan
et al.
Unproven stem cell-based interventions & harm to existing & future patients
F Naylor,
K Matthews
“This is not a sustainable model.”
J DePinto,
R Richards
View all
Latest content
What does Plug-and-Play offer large-scale AAV manufacturing?
M Neri
C Wartel-Weill
Margherita Neri
Vector process Development Manager at MolMed SpA
Claire Wartel-Weill
Director, Quality & Compliance
22 March 2022
Watch now
Flexible and scalable solutions for AAV viral vector production using a templated...
E Fong
Eva Fong
Principal Scientist, Virus and Gene Therapy Bioprocessing at MilliporeSigma
17 March 2022
Watch now
Automated GMP-compliant PSC banking in a closed system
C Sheng, PhD
R Krol, PhD
Chao Sheng, PhD
Global Product Manager - Regenerative Medicine at Miltenyi Biotec
Rafal Krol, PhD
Principal Investigator at CiRA Foundation
15 March 2022
Watch now
Accelerate your cell and gene therapy workflows with next-generation analytical...
C Heger, PhD
Chris Heger, PhD
Director, Applications Science, Analytical Solutions Division at Bio-techne
8 March 2022
Watch now
Simplifying analytical development for viral vector production: robust and...
S Kashi Ranganath
Srinath Kashi Ranganath
Staff Scientist, Field Applications, Pharma Analytics Group at Thermo Fisher Scientific
3 March 2022
Watch now
Rethink CAR T cell therapy with a scalable RNA lipid nanoparticle platform
A Zhang, PhD
R Geczy, PhD
Angela Zhang, PhD
Senior Product Manager at Precision NanoSystems Inc
Reka Geczy, PhD
Product Development Scientist at Precision NanoSystems Inc
1 March 2022
Watch now
Introducing Lonza’s AAV suspension transient transfection platform to de-risk...
S Sanyal
Suparna Sanyal
Head of Viral Vectors Commercial Development at Lonza Pharma & Biotech
24 February 2022
Watch now
Manufacturing of RCA-free adenoviral vectors
N Scheer
Nico Scheer
Senior Consultant Business Development at CEVEC Pharmaceuticals GmbH
22 February 2022
Watch now
Manufacturing of RCA-free adenoviral vectors
N Scheer
Nico Scheer
Senior Consultant Business Development, CEVEC Pharmaceuticals
27 March 2022
Poster
View all
×
Please enter your email to register
Register